Inside Amgen: A biologics leader driving volume growth through cardiometabolic and rare disease innovation

Business Synopsis & Direction Amgen is a global biotechnology leader discovering and manufacturing complex biologics for serious illnesses. To counter industry-wide price pressures, the company relies on a volume-driven growth strategy to reach massively underpenetrated patient populations.

Leadership is currently prioritizing cardiovascular health, rare disease expansion, and its highly anticipated late-stage obesity pipeline.

Differentiation & Products Amgen differentiates itself through decades of expertise in large-molecule manufacturing and a predominantly U.S.-based supply chain.

Clinically, the company stands out with its bispecific T-cell engager (BiTE) platform, which is redefining oncology care with standard-of-care therapies like IMDELLTRA. Meanwhile, its emerging obesity asset MariTide utilizes a unique antibody backbone, enabling steady drug exposure and the potential for monthly or quarterly dosing, unlike competing weekly peptides.

Strategy & Key Priorities Head of R&D Jay Bradner and Head of Commercial Murdo Gordon highlight Amgen's top priorities: advancing MariTide’s six Phase III trials and leveraging groundbreaking outcomes data to push Repatha into primary cardiovascular prevention. CFO Peter Griffith anchors these goals by allocating capital toward internal innovation and network capacity to support the company's impressive 14% product volume growth.

All sourced directly from Amgen's own leadership from earnings calls and analyst briefings.